Tumor Targeted Sickle Erythroid Precursors, Progenitors and Hematopoietic Stem Cells, Induced Pluripotent Stem Cells, Microparticles and Liposomes for Treatment of Cancer

摘要

The present invention contemplates a method of treating cancer comprising CD47 deficient sickle cell erythroid precursors/progenitors or hematopoietic stem cells transduced with viral altered genomic DNA from normal or tumor bearing hosts and used to polarize macrophages and/or activate a cytotoxic T cell tumoricidal response.